Clinical Trial: Pembrolizumab for the Treatment of High-Grade Vulvar, Vaginal, or Cervical Intraepithelial Neoplasia

U.S., Jan. 16 -- ClinicalTrials.gov registry received information related to the study (NCT04712851) titled 'Pembrolizumab for the Treatment of High-Grade Vulvar, Vaginal, or Cervical Intraepithelial Neoplasia' on Jan. 12.

Brief Summary: This phase II trial studies the effect of pembrolizumab on high-grade vulvar, vaginal, and cervical intraepithelial neoplasia. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Study Type: Interventional

Condition: * Cervical Intraepithelial Neoplasia

* Cervical Squamous Cell Carcinoma In Situ

* Cervical Squamous Intraepithelial Neoplasia 2

* Vaginal Intraepithelial...